Granulomatosis with polyangiitis is a rare condition that causes inflammation in the smallest blood vessels throughout the body, especially in the nose, sinuses, lungs, and kidneys. Early and effective treatment can help people live full, active lives, while new research continues to explore better ways to control this complex disease.

How Treatment Aims to Control the Disease

When someone receives a diagnosis of granulomatosis with polyangiitis, often simply called GPA, the primary goal of treatment is to bring the disease under control and then keep it that way. This condition, which used to be known as Wegener’s granulomatosis, requires careful management because it can affect multiple organs at once. Without treatment, it can become life-threatening, but modern medicine offers real hope.^[1]

Treatment for GPA follows a two-stage approach. The first stage focuses on stopping the active inflammation and bringing symptoms under control. This is called remission induction. The second stage, called remission maintenance, aims to keep the disease quiet for as long as possible. The specific medicines and approaches used depend on how severe the disease is, which organs are affected, and each person’s overall health.^[3]

The severity of GPA influences treatment decisions significantly. Medical professionals classify the disease into different categories, from limited disease affecting only the upper respiratory tract to severe disease that threatens vital organs like the kidneys or lungs. Someone with mild GPA affecting only the sinuses may need less aggressive treatment than someone whose kidneys are failing. Understanding where a person falls on this spectrum helps doctors tailor the treatment plan.^[10]

Early diagnosis and prompt treatment make a substantial difference in outcomes. Before modern treatments became available in the 1970s, about 90 percent of people with untreated GPA died within two years, usually from respiratory or kidney failure. Today, with appropriate treatment started early, most people can achieve remission and live relatively normal lives, though they need ongoing monitoring because the disease can return.^[10]

Standard Medications and Therapies

The foundation of GPA treatment rests on medicines that calm down the overactive immune system. Corticosteroids, particularly prednisone, are almost always used when someone first gets diagnosed or has a flare-up. These powerful anti-inflammatory drugs work quickly to reduce the swelling in blood vessels and help control symptoms. Doctors typically start with high doses and gradually reduce them as the inflammation comes under control.^[3]

For the initial stage of bringing severe GPA under control, doctors have traditionally used a chemotherapy drug called cyclophosphamide. This medicine suppresses the immune system and helps stop it from attacking the body’s own blood vessels. Cyclophosphamide combined with corticosteroids remained the standard treatment for decades, helping about 90 percent of people achieve remission. However, cyclophosphamide can cause significant side effects, including bladder problems, increased infection risk, and potential fertility issues, especially when used for extended periods.^[10]

A newer option for inducing remission is rituximab, a biological medicine that targets specific immune cells called B-cells. In 2011, rituximab became the first medication specifically approved by regulatory authorities for treating GPA. Clinical studies showed that rituximab works just as well as cyclophosphamide for bringing GPA under control, but it tends to cause fewer serious side effects. Because of this, current medical guidelines now suggest rituximab as a preferred option over cyclophosphamide for many patients with active, severe GPA.^[10][12]

Another medication approved for GPA is avacopan. This drug works differently from traditional immunosuppressants by blocking a specific part of the immune response. Doctors may use avacopan along with steroids or other treatments, particularly for patients who need an alternative to high-dose corticosteroids.^[3]

Once the disease is under control, treatment shifts to keeping it that way. For this maintenance phase, doctors typically use milder immunosuppressive medicines. Methotrexate is commonly prescribed for people with less severe GPA. It helps prevent relapses while generally causing fewer side effects than cyclophosphamide. Another option is azathioprine, which also helps maintain remission once it has been achieved.^[3][13]

The duration of treatment varies considerably among individuals. Some people may need maintenance therapy for just a few years, while others may require it much longer. Doctors make decisions about how long to continue treatment based on factors such as how well the disease is controlled, whether there have been any relapses, and how well the person tolerates the medications. Regular blood tests and other monitoring help guide these decisions.^[3]

All of these medicines can cause side effects that range from mild to serious. Corticosteroids, especially when used long-term or at high doses, can lead to weight gain, high blood pressure, diabetes, bone thinning, mood changes, and increased susceptibility to infections. Immunosuppressive drugs like cyclophosphamide, methotrexate, and azathioprine all increase the risk of infections because they weaken the immune system. Cyclophosphamide can damage the bladder and, rarely, increase the risk of certain cancers years later. Rituximab can cause reactions during the infusion, though these are usually manageable with pre-medications.^[10][12]

Innovative Treatments in Clinical Research

While current treatments can control GPA in most people, researchers continue searching for therapies that work better, cause fewer side effects, and help more people achieve lasting remission. Clinical trials test these promising new approaches before they become widely available, and participating in such trials gives some patients access to cutting-edge treatments while contributing to medical knowledge.

Clinical trials typically progress through several phases. Phase I trials test a new drug’s safety in small groups of people, determining what doses are safe and what side effects might occur. Phase II trials expand testing to larger groups to see if the drug actually works against the disease and to continue monitoring safety. Phase III trials compare the new treatment directly with current standard treatments in large groups of patients, often across multiple medical centers or even countries. If a drug proves safe and effective through these phases, regulatory agencies may approve it for general use.^[4]

Because GPA involves abnormal antibodies called ANCA (antineutrophil cytoplasmic antibodies), much research focuses on targeting the immune pathways that produce these antibodies. Scientists have discovered that approximately 90 percent of people with GPA have ANCA in their blood, and these antibodies seem to play a role in causing the blood vessel inflammation. Understanding this has opened new avenues for developing targeted therapies.^[6][8]

Researchers are exploring various biological medicines that target specific parts of the immune system. Some experimental therapies aim to block particular molecules that immune cells use to communicate with each other, potentially stopping the inflammatory cascade before it damages blood vessels. Others focus on removing harmful antibodies from the bloodstream or preventing their production in the first place.

One area of active investigation involves finding alternatives to long-term corticosteroid use. While steroids effectively control inflammation, their side effects can significantly impact quality of life, especially when needed for months or years. Newer drugs that can control inflammation without steroid-related complications would represent a major advance for people with GPA.

Clinical trials for GPA take place at specialized medical centers around the world, including in the United States, Europe, and other regions. To participate, patients typically need to meet specific criteria, such as having a confirmed diagnosis of GPA, being in a certain stage of disease, and not having certain other health conditions. Some trials look for people who have just been diagnosed, while others seek participants whose disease has returned despite treatment or who have not responded to standard therapies.^[4]

The evaluation of new treatments involves careful measurement of specific outcomes. Researchers track whether symptoms improve, how quickly remission occurs, whether organ function improves or stabilizes, what side effects appear, and how long remission lasts. They also use blood tests to monitor ANCA levels and markers of inflammation, as well as imaging studies to assess changes in affected organs. Comparing these results between people receiving the new treatment and those receiving standard treatment helps determine whether the experimental approach offers real benefits.

Most common treatment methods

• Corticosteroids
  • Prednisone is the most commonly used corticosteroid for GPA, prescribed to reduce inflammation in blood vessels
  • Typically started at high doses during active disease and gradually reduced as symptoms improve
  • Used in combination with other immunosuppressive medications rather than alone
  • Can cause side effects including weight gain, high blood pressure, diabetes, bone thinning, and increased infection risk, especially with long-term use
• Immunosuppressive Chemotherapy
  • Cyclophosphamide has been a standard treatment for severe GPA since the 1970s, helping achieve remission in about 90 percent of patients
  • Works by suppressing the overactive immune system that attacks blood vessels
  • Can cause bladder problems, fertility issues, and increased infection risk
  • Now often reserved for cases where biological therapies are not suitable or available
• Biological Therapy
  • Rituximab targets specific immune cells called B-cells and is now a preferred option for remission induction in severe GPA
  • FDA-approved in 2011 specifically for GPA treatment when combined with glucocorticoids
  • Clinical studies showed effectiveness comparable to cyclophosphamide but with a generally better safety profile
  • Can cause infusion reactions, though these are usually manageable with pre-medications
  • Avacopan represents a newer biological approach that blocks specific immune pathways
• Maintenance Immunosuppressive Therapy
  • Methotrexate is commonly used for maintaining remission in patients with less severe GPA
  • Azathioprine serves as another maintenance option after remission has been achieved
  • These medicines help prevent disease relapse while generally causing fewer side effects than induction therapies
  • Continued for varying durations depending on individual disease behavior and response